As the Unitaid-funded ASCENT project launches the main research phase, investigating the effectiveness of digital adherence technologies and data-driven support interventions on TB treatment completion and success rates, Unitaid asked the researchers leading the study to tell more about their work and its potential impact.

The Hague / Geneva, 4 August 2021 – A large global study which aims to determine if digital adherence technologies (DATs) can provide more patient-friendly approaches to improve tuberculosis (TB) treatment outcomes launches in Ethiopia, Tanzania, South Africa, the Philippines and Ukraine, as part of the ASCENT project.

Geneva, 30 January 2020 – Unitaid will invest US$ 39 million in two projects to speed up the development of long-acting versions of medicines for low- and middle-income countries. Innovative ways to administer drugs, which have revolutionized contraception and the treatment of schizophrenia, could redefine prevention and treatment of infectious diseases, but remain at early stages of research because of market barriers.

Hyderabad, India – Unitaid and partners launched a trio of innovations today (November 1) that will work together to fight tuberculosis through gene-based diagnosis, better treatments and ingenious technologies that help patients remember to take their medicines.

Geneva, 23 July 2019 – The KNCV Tuberculosis Foundation and Unitaid signed a US$ 13.9 million grant agreement on Tuesday to increase the use of smart pillboxes and mobile technology, aiming to help patients adhere to their medicines and raise the world’s plateauing cure rates for TB.

Geneva – The Foundation for Innovative New Diagnostics (FIND) and Unitaid signed a US$ 14.5 million grant Thursday (July 4) to deploy a powerful new technology in the diagnosis of drug-resistant tuberculosis.

Geneva, 29 May 2019 –Unitaid and UNICEF will collaborate to save the lives of more children, adolescents and mothers, an agreement formalized by a memorandum of understanding signed today.

Tokyo, 2 April 2019 — Unitaid Executive Director Lelio Marmora and Parliamentary Vice-Minister for Foreign Affairs of Japan Kenji Yamada met today to discuss a new alignment between Japan’s global health priorities and Unitaid’s work in fighting tuberculosis.

Geneva – A Unitaid-funded study has found that 3HP, a new, shorter preventive therapy for tuberculosis, is safe for people who also take the HIV drug dolutegravir. The results mark a critical milestone for countries and funding partners seeking to expand preventive TB therapy.

Geneva – Unitaid is pleased to announce a call for proposals for projects speeding development of long-acting versions of medicines that could potentially revolutionize treatment and prevention of diseases including HIV, tuberculosis and malaria in low- and middle-income countries.